Author:
Ostuzzi G.,Papola D.,Gastaldon C.,Barbui C.
Abstract
Three-month long-acting paliperidone is a new, recently marketed, formulation of paliperidone, characterised by the longest available dosing interval among long-acting antipsychotics. The clinical profile of 3-month long-acting paliperidone was recently summarised by the European Medicines Agency (EMA) in a public assessment report, released in April 2016. In this commentary, the main strengths and limitations of the EMA assessment report were appraised and discussed, in order to highlight possible implications for clinical practice, future research and regulatory practices for drug approval.
Publisher
Cambridge University Press (CUP)
Subject
Psychiatry and Mental health,Public Health, Environmental and Occupational Health,Epidemiology
Reference18 articles.
1. Regulatory Scientific Advice on Non-Inferiority Drug Trials
2. Superiority, equivalence or non-inferiority?
3. Through the looking glass: understanding non-inferiority
4. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study
5. European Medicines Agency, Committee for Medicinal Products for Human Use (2012). Guideline on Clinical Investigation of Medicinal Products, Including Depot Preparations in the Treatment of Schizophrenia. EMA/CHMP/40072/2010 Rev. 1. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/10/WC500133437.pdf.
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献